Infex candidate nominated for COV-X programme
Therapy targets the coronavirus PLPRO enzyme essential for the evasion of host immune response
Read More
Tag: Infex
Positive study results for Infex’s RESP-X
Data demonstrates a sound safety and tolerability profile for therapy during phase 1 clinical trial
Read More
Infex begins study of pseudomonas aeruginosa candidate RESP-X
Phase 1 research will evaluate tolerability and safety of therapy among healthy volunteers
Read More
- Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
- IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease
- En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation
- ALK’s EURneffy receives positive CHMP opinion for emergency anaphylaxis treatment in children
- CERo reports encouraging early data from phase 1 trial of CER‑1236
